Treatment-associated musculoskeletal and vasomotor symptoms and relapse-free survival in the NCIC CTG MA.27 adjuvant breast cancer aromatase inhibitor trial

Journal of Clinical Oncology

Volumn 33, Issue 3, 2015, Pages 265-271

  Stearns, Vered ^a   Chapman, Judith Anne W ^b   Le Maitre, Aurélie ^b   Kundapur, Jessica ^b   Shepherd, Lois E ^b   Pritchard, Kathleen I ^c   Ma, Cynthia X ^d   Ellis, Matthew J ^e   Ingle, James N ^f   Budd, G Thomas ^g   Sledge, George W ^h   Liedke, Pedro E R ^i,l   Goss, Paul E ^i,j   Rabaglio, Manuela ^k  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b QUEEN S UNIVERSITY   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d USA   (United States)

^e BAYLOR COLLEGE OF MEDICINE   (United States)

^f MAYO CLINIC   (United States)

^g LERNER RESEARCH INSTITUTE   (United States)

^h STANFORD UNIVERSITY   (United States)

ⁱ HARVARD UNIVERSITY   (United States)

^j MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^k UNIVERSITY OF BERN   (Switzerland)

^l HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANASTROZOLE; CELECOXIB; EXEMESTANE; RALOXIFENE; TRASTUZUMAB; ANDROSTANE DERIVATIVE; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; AROMATASE INHIBITOR; NITRILE; TRIAZOLE DERIVATIVE;

ADULT; ARTHROPATHY; ARTICLE; BREAST CANCER; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MIDDLE AGED; MUSCULOSKELETAL DISEASE; OPEN STUDY; PHASE 3 CLINICAL TRIAL; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENCE FREE SURVIVAL; RECURRENT DISEASE; SYMPTOM ASSESSMENT; VASOMOTOR DISORDER; ADJUVANT CHEMOTHERAPY; ADRENERGIC SYSTEM; AGED; BREAST NEOPLASMS; CHEMICALLY INDUCED; DISEASE FREE SURVIVAL; DRUG EFFECTS; HOT FLUSH; KAPLAN MEIER METHOD; MUSCULOSKELETAL SYSTEM;

ADULT; AGED; ANDROSTADIENES; ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; FEMALE; HOT FLASHES; HUMANS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; MUSCULOSKELETAL SYSTEM; NITRILES; TRIAZOLES; VASOMOTOR SYSTEM;

EID: 84921735027     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.57.6926     Document Type: Article

References (20)

1. Burstein HJ, Prestrud AA, Seidenfeld J, et al: American Society of Clinical Oncology clinical practice guideline: Update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol 28:3784-3796, 2010
2. Crew KD, Greenlee H, Capodice J, et al: Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer. J Clin Oncol 25:3877-3883, 2007
3. Henry NL, Giles JT, Ang D, et al: Prospective characterization of musculoskeletal symptoms in early stage breast cancer patients treated with aromatase inhibitors. Breast Cancer Res Treat 111:365-372, 2008
4. Mao JJ, Stricker C, Bruner D, et al: Patterns and risk factors associated with aromatase inhibitor-related arthralgia among breast cancer survivors. Cancer 115:3631-3639, 2009
5. Cuzick J, Sestak I, Cella D, et al: Treatment-emergent endocrine symptoms and the risk of breast cancer recurrence: A retrospective analysis of the ATAC trial. Lancet Oncol 9:1143-1148, 2008
6. Fontein DB, Seynaeve C, Hadji P, et al: Specific adverse events predict survival benefit in patients treated with tamoxifen or aromatase inhibitors: An international tamoxifen exemestane adjuvant multinational trial analysis. J Clin Oncol 31:2257-2264, 2013
7. Huober J, Cole BF, Rabaglio M, et al: Symptoms of endocrine treatment and outcome in the BIG 1-98 study. Breast Cancer Res Treat 143:159-169, 2014
8. Goss PE, Ingle JN, Pritchard KI, et al: Exemestane versus anastrozole in postmenopausal women with early breast cancer: NCIC CTG MA. 27 - A randomized controlled phase III trial. J Clin Oncol 31:1398-1404, 2013
9. Ingle JN, Schaid DJ, Goss PE, et al: Genomewide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors. J Clin Oncol 28:4674-4682, 2010
10. Wagner LI, Zhao F, Chapman J-A, et al: Patient-reported predictors of early treatment discontinuation: NCIC JMA.27/E1Z03 quality of life study of postmenopausal women with primary breast cancer randomized to exemestane or anastrozole. Cancer Res 71:114a, 2011 (abstr S6-2)
11. Solomon SD, McMurray JJ, Pfeffer MA, et al: Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 352:1071-1080, 2005
12. Ockene JK, Barad DH, Cochrane BB, et al: Symptom experience after discontinuing use of estrogen plus progestin. JAMA 294:183-193, 2005
13. Fellowes D, Fallowfield LJ, Saunders CM, et al: Tolerability of hormone therapies for breast cancer: How informative are documented symptom profiles in medical notes for "well-tolerated" treatments? Breast Cancer Res Treat 66:73-81, 2001
14. Oberguggenberger A, Hubalek M, Sztankay M, et al: Is the toxicity of adjuvant aromatase inhibitor therapy underestimated? Complementary information from patient-reported outcomes (PROs). Breast Cancer Res Treat 128:553-561, 2011
15. Chapman J-AW, Shepherd LE, Le Maitre A, et al: Effect of treatment emergent symptoms on relapse free survival: NCIC CTG MA.12 a randomized placebo-controlled trial of tamoxifen after adjuvant chemotherapy in pre-menopausal women in early breast cancer. Cancer Res 71:P1-06-08, 2011 (abstr)
16. Burstein HJ, Winer EP: Aromatase inhibitors and arthralgias: A new frontier in symptom management for breast cancer survivors. J Clin Oncol 25: 3797-3799, 2007
17. Henry NL, Giles JT, Stearns V: Aromatase inhibitor-associated musculoskeletal symptoms: Etiology and strategies for management. Oncology (Williston Park) 22:1401-1408, 2008
18. Liedke PE, Goss PE: Aromatase inhibitors and musculoskeletal adverse events. Lancet Oncol 13: 333-334, 2012
19. Henry NL, Skaar TC, Dantzer J, et al: Genetic associations with toxicity-related discontinuation of aromatase inhibitor therapy for breast cancer. Breast Cancer Res Treat 138:807-816, 2013
20. Henry NL, Azzouz F, Desta Z, et al: Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early-stage breast cancer. J Clin Oncol 30:936-942, 2012